RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Direct Medical Costs Following Pediatric Tympanostomy Tube Placement in the United States
Candrilli, S., Tam, IM., & Moss, JR. (2016). Direct Medical Costs Following Pediatric Tympanostomy Tube Placement in the United States. Value in Health, 19(3), A123. https://doi.org/10.1016/j.jval.2016.03.500
Objectives: Tympanostomy tube (TT) placement is an established treatment for recurring otitis media (OM), an ear-related condition occurring in ~90% of children by age 4 and posing a significant economic burden, with > $4B USD in annual costs. As limited data documenting economic outcomes in this area exist, this study assessed direct medical costs following TT placement in real-world settings. Methods: Insurance claims (1/2010-12/2013) of commercially insured and Medicaid-enrolled children ( = 180 days before and >= 360 days following the procedure. Predicted, adjusted medical costs (i.e., total; office and emergency room [ER] visit-related) of ear-related care, among those receiving such care during the 360-day follow-up period, were generated following estimation of multivariable generalized linear regression models. Results were generated overall, as well as stratified by commercially insured and Medicaid-enrolled patients. Results: 198,078 patients (72,932 Medicaid-enrolled, 125,146 commercially insured) met all inclusion criteria and received ear-related care in any setting during the follow-up period. This analysis revealed that in the 360 days following initial TT placement, mean (SD), predicted, adjusted total costs for earrelated conditions were $456 ($4,174). For commercially insured and Medicaid-enrolled patients, these were $555 ($5,013) and $286 ($2,035), respectively (P< 0.0001). ER-related costs for ear conditions were $187 ($247) overall, $427 ($293) for commercially insured, and $63 ($51) for Medicaid-enrolled (p< 0.0001). Finally, office visit-related costs for ear conditions were $162 ($90) overall, $195 ($86) for commercially insured and $102 ($64) for Medicaid-enrolled (p< 0.0001). Conclusions: Predicted, adjusted costs are significantly greater in commercially insured patients, demonstrating significantly lower reimbursement to providers who care for Medicaid pediatric patients. Health care decision makers should be aware of these findings as they develop plans to allocate resources in the pediatric setting.